Roche-Lilly Blood Test Clears FDA: What It Means for Alzheimer's Screening

The test is here. The real question is who gets it—and what happens next.

The FDA cleared the Elecsys Phospho‑Tau (217P) Plasma blood test on Monday, a single‑biomarker assay that Roche and Eli Lilly say can identify amyloid pathology linked to Alzheimer’s disease in patients over age 55. In practice, that means doctors can now order a routine blood draw instead of scheduling an expensive PET scan or a lumbar puncture to check for the plaques that define the disease.

That simplicity is the breakthrough. But the clearance comes with a crucial caveat: the test is not a standalone diagnosis of Alzheimer’s. It must be interpreted alongside clinical information—cognitive scores, medical history, other biomarkers. The companies are calling it a “minimally invasive” tool designed to fit into existing lab workflows, requiring no new equipment.

Labcorp and Quest Diagnostics said they will begin offering the test as soon as logistics allow. That distribution muscle matters. The United States already has the second approved blood test for amyloid—the Fujirebio assay cleared last May—but those first tests remain largely confined to specialty clinics and research sites. A nationwide rollout through two of the largest commercial labs could change that overnight.

Why this test matters, right now

Alzheimer’s remains a disease of missed signals. An estimated 6.7 million older adults in the U.S. are living with a diagnosis, but experts believe the true number is far higher. Globally, roughly 75% of dementia cases go undiagnosed, a figure driven partly by the stigma of symptoms and partly by the barriers to testing. PET scans cost thousands and require specialized facilities; spinal taps are invasive and uncomfortable. Many patients, especially in rural areas or under‑resourced health systems, never get the answer.

The p‑tau217 blood test targets one specific pathology—amyloid accumulation—but it is the most common underlying driver of Alzheimer’s. For clinicians, a positive result can help justify referral to a neurologist, initiation of monitoring, or consideration of emerging disease‑modifying therapies. For patients, it offers a chance at clarity without the ordeal of a PET or lumbar puncture.

That is the promise. The reality is more complicated.

Who wins, who loses

Patients in communities with limited neurology access stand to gain most. A primary‑care physician can now order a blood test, get a preliminary amyloid result, and decide whether further work‑up is warranted. That could shave months off the diagnostic odyssey—a timeline that currently stretches across multiple referrals, specialist waitlists, and insurance battles.

Health systems may see reduced costs for imaging and specialist consultations, at least in the early‑stage triage. Labs will gain a new revenue stream. Pharma companies—Roche and Eli Lilly are also developing anti‑amyloid therapies—stand to benefit from a larger pool of identified candidates for clinical trials and, eventually, prescription.

But some players lose ground. Providers of PET scans and cerebrospinal fluid analysis face declining demand for amyloid detection. A single report from the American Association of Neurological Surgeons estimated that amyloid PET utilization could drop by as much as 40% in health systems that adopt blood‑based screening aggressively. Neurologists who relied on those invasive methods as gatekeepers may find their role evolving rather than disappearing.

Insurance companies will have to decide whether to cover the test widely—and at what price—before they can reap the long‑term savings of earlier intervention. Actuarial models from several major payers suggest that covering p‑tau217 testing for Medicare beneficiaries over 65 could generate net savings within three to five years, given the reduced need for imaging and the potential to slow disease progression with earlier treatment. But those savings remain theoretical until coverage policies are written.

The test also does not replace the clinician’s judgment. A positive amyloid result does not mean a patient has Alzheimer’s dementia; it means the pathology is present. Many older adults carry amyloid without cognitive decline—studies suggest up to 30% of cognitively normal individuals over 70 show amyloid on PET imaging. Without careful counseling, broad screening could create anxiety and unnecessary referrals, flooding already strained specialty networks with patients who may never progress to symptomatic disease.

The second‑order effects

Beyond the immediate clinical and commercial implications, this clearance sets off a chain reaction across the Alzheimer’s ecosystem. Diagnostic companies that built their business models around PET imaging and CSF analysis now face a structural shift. Some are pivoting to position themselves as complementary rather than competitive—offering confirmatory testing for ambiguous blood results or targeting populations where blood tests are less accurate, such as patients with certain genetic variants or comorbid conditions.

Primary care is arguably the most disrupted specialty. For decades, PCPs have referred suspicious patients downstream with little to act on in between. The blood test hands them a new instrument—one that changes the dynamics of the referral conversation from “we need to figure out if this is dementia” to “here’s what we found; now let’s plan next steps.” That shift requires new workflows, new patient education materials, and new comfort levels with interpreting biomarker results.

Health equity advocates are watching closely. While the test has the potential to close access gaps, it could also widen them if pricing and coverage decisions restrict it to well‑insured populations. Rural hospitals, federally qualified health centers, and safety‑net systems will need explicit support to integrate the test into existing pathways—not just logistical ability to send tubes to a central lab, but the clinical infrastructure to follow up on results.

The global ripple

The United States is often the first to clear new diagnostics, but the implications extend far beyond its borders. In Europe, where health systems are slower to adopt innovative tests, this clearance could accelerate debates about reimbursement and access. The European Medicines Agency is expected to review the data under its parallel assessment pathway, potentially granting approval within months rather than years. Several European national health services have already signaled interest in pilot programs.

In low‑ and middle‑income countries, where Alzheimer’s care is sparse, a simple blood test could be the difference between diagnosis and oblivion. Organizations like the World Health Organization have called for expanded dementia diagnosis capacity as a priority, noting that fewer than 1 in 8 countries have national dementia plans. A blood test eliminates the need for imaging infrastructure that most low‑resource settings simply cannot build. But without pricing commitments from Roche and Eli Lilly—and without integration into national health programs—the test may remain a luxury accessible only through private clinics in capital cities.

What comes next

The FDA’s clearance is a milestone, not a finish line. The next step is implementation: Will Labcorp and Quest launch the test at scale? Will insurers cover it? Will primary‑care physicians feel confident ordering it? And crucially, will it lead to more patients receiving disease‑modifying therapies before irreversible damage occurs?

Roche and Eli Lilly have not announced pricing yet, a deliberate choice that leaves the market guessing. Industry observers expect a per‑test cost in the range of $500 to $800, which would place it below the $2,000 to $5,000 typical for amyloid PET scans—but still a significant outlay for self‑pay patients. Insurance coverage decisions are expected to cascade over the coming months, with Medicare likely to issue a national coverage determination after reviewing the clinical evidence.

For now, the test offers a beacon. It confirms that the long‑sought holy grail of a simple, accurate blood test for Alzheimer’s is real. But the road from detection to intervention is still wide and uneven. The breakthrough is not the test itself—it is the question it forces us to ask: if we can now easily identify who is at risk, do we have the systems, the therapies, and the will to act?